ADMA Biologics (ADMA) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed ADMA Biologics (ADMA) over the past year, gaining 98.0% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with -61.5% for PVLA. ADMA Biologics is the larger company by market cap ($2.32 billion vs $2.00 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | PVLA |
|---|---|---|
| Share price | $10.36 | $138.77 |
| Market cap | $2.32B | $2.00B |
| 1-day change | +0.29% | +5.66% |
| YTD return | -43.20% | +32.58% |
| 1-year return | -29.72% | +97.99% |
| 5-year return | +841.82% | -61.54% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | — |
| Revenue growth (YoY) | +19.63% | — |
| Net income (latest FY) | $146.93M | $-41.72M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | — |
| Net margin | 28.80% | — |
| 52-week high | $20.46 | $161.38 |
| 52-week low | $7.21 | $66.58 |
| Distance from 52-week high | -49.36% | -14.01% |
| Analyst consensus | none | none |
| Avg. price target upside | +64.09% | +66.12% |
| Average volume | 2.66M | 211.30K |
| Shares outstanding | 223.98M | 14.41M |
| Employees | 640 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed ADMA by 127.7 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Healthcare · Biotechnology · 29 employees
ADMA vs PVLA FAQ
Which is bigger, ADMA Biologics or Palvella Therapeutics?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.32B compared with $2.00B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, ADMA or PVLA?
PVLA returned +97.99% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.